SARS-CoV-2

In his weekly clinical update, Dr. Griffin discusses the Marburg virus outbreak in Rwanda, the lack of immune durability following pertussis vaccination, recommendations for maternal vaccination and antibody therapy to protect against infant RSV, vaccine…

In his weekly clinical update, Dr. Griffin deep dives into the durability of the antibody response following mpox vaccination, vaccine security, global mpox circulation, the origins of SARS-CoV-2, including a list TWiV episodes and combatting…

In his weekly clinical update, Dr. Griffin dives into West Nile virus in New Jersey, poliovirus vaccination campaign in Gaza and Afghanistan, California dengue virus infections, children dying from flu, mpox vaccination procurement and antiviral usage, flu circulation in US, before reviewing the recent statistics on SARS-CoV-2 infection, finding a new wasterwater dashboard, if the monovalent XBB.1.5 COVID-19 vaccine is effective against circulating SARS-CoV-2 isolates, the need for nasal mucosal IgA in response to SARS-CoV-2 infection, where to find PEMGARDA, does administration of molnupiravir reduce symptoms in the vaccinated, when to use convalescent plasma, how molnupiravir treatment leads to better outcomes 3 and 6 months after treatment, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if vaccination against SARS-CoV-2 does protect against long COVID, and if those taking the anti-diabetic drug metformin have higher or lower incidences of long COVID.

In his weekly clinical update, Dr. Griffin dives into “pandemic potential” viruses isolated from farmed fur animals, how the mRNA and pox vectored vaccines against mpox spar against each other, how telehealth does managing mpox, and if prophylactic use of the anti-RSV monoclonal for infants is cost-effective before reviewing the recent statistics on SARS-CoV-2 infection, if viral load correlates to one vaccination status, where to find PEMGARDA, does administration of molnupiravir reduce symptoms in the vaccinated, when to use convalescent plasma, how molnupiravirs treatment leads to better outcomes 3 and 6 months after treatment, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if vaccination against SARS-CoV-2 does protect against long COVID, and if SARS-CoV-2 during Omicron alters ones’ micriobiota.

In his weekly clinical update, Dr. Griffin discusses seasonal influenza vaccine recommendations from the CDC, polio vaccine campaign securing mpox vaccine for Africa, and donating to reduce food insecurity in mpox affected areas before reviewing the recent statistics on SARS-CoV-2 infection, where to find PEMGARDA, when to use convalescent plasma, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if vaccination against SARS-CoV-2 does protect against long COVID, how fibrin drives thromboinflammation and neuropathology in COVID-19, and an evidence based approach to long COVID.

In his weekly clinical update, Dr. Griffin discusses Dr. Fauci’s case of West Nile virus, polio vaccine campaign develops in Gaza, disease that associates with Oropouche virus, mpox: vaccines, clinical trial for mpox antiviral and the WHO strategic preparedness and response plan before reviewing the recent statistics on SARS-CoV-2 infection, how to obtain free COVID tests, EUA for updated Novavax COVID vaccine, ISDA support of and where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if nirmatrelvir/ritonavir is effective at preventing hospitalization of high risk patients, incidence of mental illness in the vaccinated and unvaccinated, the effect of amubarvimab/romlusevimab on long COVID outcome, having an evidence based approach to long COVID and how fibrin drives thromboinflammation and neuropathology in COVID-19.

In his weekly clinical update, Dr. Griffin discusses global transmission of mpox, the different clades of the virus and associated pathogenesis, vaccination vs antiviral therapy against mpox and the US’s aid response for controlling the African outbreak before reviewing the recent statistics on SARS-CoV-2 infection, authorization and approval of updated COVID vaccines, the economic benefit of an annual COVID vaccine and if the first updated vaccines against XBB.1.5 were effective, where to find PEMGARDA, breakthrough infections when administering PEMGARDA, when to use convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and how long COVID differs in children and adolescents.